

sity comparable to Americans for Nonsmokers' Rights.

Lott expresses the libertarian view that physicians and governments should stay out of attempts to change individual behavior, even if that behavior is harmful. The same argument could be made for mandatory use of seat belts in automobiles and helmets for motorcycle riders, drunk-driving legislation, and the use of fluoride to combat dental caries.⁴ In the case of tobacco use and obesity, I would be more sympathetic to Lott's argument were it not for the huge marketing efforts of the tobacco and food industries, which, if unopposed, would be even more influential than they already are. Although I agree that clinical efforts should avoid coercion and stigmatization, I come

down on the side of urging clinicians to do all they can to improve the health of the public.

Steven A. Schroeder, M.D.

University of California at San Francisco
San Francisco, CA 94143
schroeder@medicine.ucsf.edu

1. Department of Health and Human Services. The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General: 2006. Washington, DC: Government Printing Office, 2006.
2. Mokdad AH, Marks JS, Stroup JS, Gerberding JL. Actual causes of death in the United States, 2000. *JAMA* 2004;291:1238-45. [Erratum, *JAMA* 2005;293:293-4.]
3. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. *JAMA* 2005;293:1861-7.
4. Isaacs SL, Schroeder SA. Where the public good prevailed: lessons from success stories in health. *American Prospect* 2001; 12:26-30.

Control of Neglected Tropical Diseases

TO THE EDITOR: Hotez et al. (Sept. 6 issue)¹ present an excellent review of current global approaches to neglected tropical diseases. However, vigilant ongoing (post-intervention) surveillance to ensure that these diseases do not rebound should not be ignored. The integration of disease-control programs using a "rapid-impact package of drugs" is a feasible and probably cost-effective way to improve the quality of life for billions of people. The authors advocate monitoring and evaluation to judge the success of these programs but do not emphasize ongoing surveillance. Although surveillance may present a resource challenge in many environments, it also poses a statistical challenge as these heterogeneously distributed parasitic diseases become less common. A comprehensive, integrated surveillance plan should be incorporated into the cost estimates for the control or elimination of neglected tropical diseases. New approaches for determining the burden of these diseases as they become less prevalent should include improved diagnostic tools and novel epidemiologic techniques.

Clare Huppertz, B.M., B.S., M.P.H.

National Centre for Epidemiology and Population Health
Canberra 0200, Australia
clare.huppertz@hnehealth.nsw.gov.au

David N. Durrheim, M.B., Ch.B., Dr.P.H.

Hunter Medical Research Institute
Newcastle 2310, Australia

1. Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. *N Engl J Med* 2007;357:1018-27.

THE AUTHORS REPLY: Huppertz and Durrheim comment on the need for surveillance. For the neglected tropical diseases, control and surveillance strategies are determined by the epidemiology and by the precise objectives of the intervention. For example, human African trypanosomiasis was controlled yet resurged during the period from the 1960s to the 1990s in Angola, Democratic Republic of the Congo, and Sudan, because surveillance stopped, health systems collapsed, and the mobile-team approach was abandoned.¹ Today, human African trypanosomiasis is again under control, and effective surveillance is crucial in order to avoid a new resurgence. In contrast, soil-transmitted helminthiasis and schistosomiasis require regular preventive mass chemotherapy to reduce severe morbidity, and subsequent monitoring of lot quality assurance sampling is enough.^{2,3} With lymphatic filariasis, onchocerciasis, and trachoma, surveillance after control must monitor reduction of transmission. The critical tools referred to by Huppertz and Durrheim are being developed or deployed. However, cost and expertise are constraints on routine use, because health systems are overburdened and human resources are scarce where neglected tropical diseases are prevalent. Sadly, introducing routine surveillance

of neglected tropical diseases in health management information systems will be challenging, given the diversity of epidemiology and health systems.

David Molyneux, Ph.D., D.Sc.

Liverpool School of Tropical Medicine
Liverpool L3 5QA, United Kingdom

Alan Fenwick, Ph.D.

Imperial College London
London W2 1PG, United Kingdom

Lorenzo Savioli, M.D., M.Sc.

World Health Organization
1211 Geneva, Switzerland

1. Human African trypanosomiasis (sleeping sickness): epidemiological update. *Wkly Epidemiol Rec* 2006;81(8):71-80.
2. Brooker S, Kabatereine NB, Myatt M, Stothard JR, Fenwick A. Rapid assessment of *Schistosoma mansoni*: the validity, applicability and cost-effectiveness of the Lot Quality Assurance Sampling method in Uganda. *Trop Med Int Health* 2005;10:647-58.
3. Preventive chemotherapy in human helminthiasis — coordinated use of anthelmintic drugs in control interventions: a manual for health professionals and programme managers. Geneva: World Health Organization, 2006.

Myocardial Reperfusion Injury

TO THE EDITOR: In the article by Yellon and Hausenloy (Sept. 13 issue)¹ on myocardial perfusion injury, I would like to challenge the statement about therapeutic hypothermia, since this method is emerging as a novel way to reduce final myocardial infarct size. Therapeutic cooling showed a significant ST-segment resolution in the group with anterior myocardial infarction in the Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients with Acute Myocardial Infarction (COOL-MI) trial.² Patients with anterior-wall infarction and a core body temperature of 35°C or less before angioplasty had a reduction in the final infarct size, as compared with patients with a temperature of more than 35°C. Observations from the COOL-MI trial suggest that the heart needs to be cooled optimally before reperfusion in order to provide optimal myocyte and microvascular protection.

Radhakrishnan Ramaraj, M.D.

University of Arizona College of Medicine
Tucson, AZ 85724
drkutty2@gmail.com

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. *N Engl J Med* 2007;357:1121-35.
2. O'Neill W. Cooling as an adjunct to primary PCI for myocardial infarction. Presented at the Transcatheter Cardiovascular Therapeutics Conference, Washington, DC, September 18, 2003.

TO THE EDITOR: Yellon and Hausenloy discuss mechanisms of myocyte death. Readers may underestimate the relationship between the “no reflow” phenomenon and myocardial reperfusion injury.¹ Tissue perfusion is an independent predictor of death after reperfusion and is associated with infarct size, ventricular function, and the presence or absence of congestive heart failure.²

Therefore, the no-reflow phenomenon should be considered prominently in discussing mechanisms of myocardial reperfusion injury.

The authors refer to adenosine as an anti-inflammatory agent; however, adenosine has other actions (antiplatelet, vasodilatory, angiogenic, vasculogenic, and antifibrotic).¹ Preclinical studies have shown cardioprotective effects of adenosine. The Acute Myocardial Infarction Study of Adenosine (AMISTAD) I and II showed reductions in infarct size in anterior infarction (67% and 57%, respectively).^{1,3} AMISTAD II showed that adenosine given within 3 hours after the onset of symptoms decreased mortality at 6 months (7.3% in the adenosine group vs. 11.2% in the placebo group).⁴

Mervyn B. Forman, M.D.

North Atlanta Cardiovascular Associates
Atlanta, GA 30342

Edwin K. Jackson, Ph.D.

University of Pittsburgh School of Medicine
Pittsburgh, PA 15219
edj@pitt.edu

Drs. Forman and Jackson report being coinventors on a patent for the use of adenosine for myocardial infarction. The patent is owned by Vanderbilt University. No other potential conflict of interest relevant to this letter was reported.

1. Forman MB, Stone GW, Jackson EK. Role of adenosine in acute myocardial infarction. *Cardiovasc Drug Rev* 2006;24:116-47.
2. Forman MB, Jackson EK. Importance of tissue perfusion in STEMI patients undergoing reperfusion strategies: role of adenosine. *Clin Cardiol* 2007;30:583-5.
3. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). *J Am Coll Cardiol* 2005;45:1775-80.
4. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. *Eur Heart J* 2006;27:2400-5.